(Q34769059)

4 August 2017

1 reference

title

Familial hypercholesterolemia: current treatment and advances in management (English)

1 reference

familial hypercholesterolemia

4 August 2017

0 references

1 reference

5

John J P Kastelein

1 reference

4 August 2017

Roeland Huijgen

1

1 reference

4 August 2017

Maud N Vissers

2

1 reference

4 August 2017

Joep C Defesche

3

1 reference

4 August 2017

Peter J Lansberg

4

1 reference

4 August 2017

Barbara A Hutten

6

1 reference

4 August 2017

publication date

1 April 2008

1 reference

Expert Review of Cardiovascular Therapy

4 August 2017

published in

1 reference

4 August 2017

volume

6

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

567-581

1 reference

Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Update of the molecular basis of familial hypercholesterolemia in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Differences in the Phenotypic Characteristics of Subjects With Familial Defective Apolipoprotein B-100 and Familial Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Common low-density lipoprotein receptor mutations in the French Canadian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Systematic family screening for familial hypercholesterolemia in Iceland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Development of coronary heart disease in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Measurement of arterial wall thickness as a surrogate marker for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Statin treatment in children with familial hypercholesterolemia: the younger, the better

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case--a modern Pandora's box.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effect of ACAT inhibition on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Liver dysfunction and steatosis in familial hypobetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Antisense apolipoprotein B therapy: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regressio

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.4.567

21 January 2018

Identifiers

DOI

10.1586/14779072.6.4.567

1 reference

4 August 2017

1 reference